<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767610</url>
  </required_header>
  <id_info>
    <org_study_id>HL-PIF-101</org_study_id>
    <nct_id>NCT01767610</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin</brief_title>
  <official_title>Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic
      characteristics of each arms after repeated administrating Lipilfen cap. 160mg and Livalo
      tab. 2mg through 3 period by separately or combinedly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To develop combination product of micronized fenofibrate plus pitavastatin, we would like to
      evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic
      characteristics of each arms after repeated administrating Lipilfen cap. 160mg(micronized
      fenofibrate 160mg)by Dae Woong Pharma. and Livaro tab. 2mg (pitavastatin Ca 2mg) by Joong Wae
      Pharm. through 3 period by separately or combinedly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-Drug interaction evaluation (Cmax,ss, Cmin,ss, Tmax,ss)</measure>
    <time_frame>just before dosing on 1st day and 4th day of each period and 0, 0.25, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48hr on final 5th dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed for the duration of study medication dosing days and hospital stay, and expected average of 3days and follow-up period for maximum 7 days from the discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>micronized fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pitavastatin Ca</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>micronized fenofibrate plus pitavastatin Ca</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized fenofibrate 160mg</intervention_name>
    <arm_group_label>micronized fenofibrate</arm_group_label>
    <other_name>Lipilfen cap. 160mg : once daily for 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin Ca 2mg</intervention_name>
    <arm_group_label>pitavastatin Ca</arm_group_label>
    <other_name>Livalo tab. 2mg : once daily for 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized fenofibrate 160mg plus pitavastatin Ca 2mg</intervention_name>
    <arm_group_label>micronized fenofibrate plus pitavastatin Ca</arm_group_label>
    <other_name>Lipilfen cap. 160mg plus Livalo tab. 2mg : once daily for 5 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Years 20-55

          2. Body weight≥50kg and 18≤BMI≤29kg/m2

          3. Volunteer

        Exclusion Criteria:

          1. Subject with serious active cardiovascular, respiratory, hepatology, renal,
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological
             disease or history of such disease

          2. Subject with symptoms of acute disease within 28days prior to study medication dosing

          3. Subject with known for history which affect on the absorption, distribution,
             metabolism or excretion of drug

          4. Subject with clinically significant active chronic disease

          5. Subject with any of the following conditions in laboratory test i. AST(aspartate
             aminotransferase) or ALT(alanine transferase) &gt; upper normal limit × 1.5 ii. Total
             bilirubin &gt; upper normal limit × 1.5 iii. renal failure with Creatinine clearance &lt;
             50mL/min iv. creatine phosphokinase &gt; upper normal limit × 2

          6. Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus
             antibody, venereal disease research laboratory test

          7. Use of any prescription medication within 14 days prior to study medication dosing

          8. Use of any medication such as over-the-counter medication including oriental
             medication within 7 days prior to study medication dosing

          9. Subject with clinically significant allergic disease (except for mild allergic
             rhinitis and mild allergic dermatitis that are not needed to administer drug)

         10. Subject with known for hypersensitivity reaction to fenofibrate, fenofibric acid or
             statin

         11. gallbladder disease

         12. Subject who experiences photo-allergy or photo-toxicity during administrating fibrates
             or ketoprofen

         13. Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose malabsorption

         14. Subject who is not albe to taking the institutional standard meal

         15. Subject with whole blood donation within 60days, component blood donation within
             20days

         16. Subjects receiving blood transfusion within 30days prior to study medication dosing

         17. Participation in any clinical investigation within 60days prior to study medication
             dosing

         18. Continued excessive use of caffeine (caffeine &gt; five cups/day),
             alcohol(alcohol&gt;30g/day) and severe heavy smoker(cigarette &gt; 10 cigarettes per day)

         19. Subjects with decision of nonparticipation through investigator's review due to
             laboratory test results or other excuse such as non-responding to request or
             instruction by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

